07:16 AM EDT, 10/20/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said Monday that a phase 1/2 trial evaluating darovasertib in combination with Pfizer's crizotinib as a first-line treatment for patients with metastatic uveal melanoma showed a median overall survival of 21.1 months.

The investigational combination therapy also demonstrated a median progression free survival of seven months, a confirmed overall response rate of 34%, a median duration of response of nine months, and a disease control rate of 90%, the company said.

Ideaya said the combination had manageable tolerability.

Shares of the company were up 3.6% in recent Monday premarket activity.